DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CANDESARTAN CILEXETIL

« Back to Dashboard

Clinical Trials for Candesartan Cilexetil

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00108706	Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)	Unknown status	Takeda	Phase 4	2004-12-01	The aim of this study is to determine whether it is safe and effective to give the Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute stroke.
NCT00108706	Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)	Unknown status	City Hospitals Sunderland NHS Foundation Trust	Phase 4	2004-12-01	The aim of this study is to determine whether it is safe and effective to give the Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute stroke.
NCT00125463	Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients	Unknown status	The Japanese Society of Hypertension	Phase 3	2001-09-01	The purpose of this study is to compare an angiotensin II receptor antagonist (candesartan cilexetil– Blopress®) and a calcium channel blocker (amlodipine besilate– Norvasc®/Amlodin®) in terms of the incidence of cardiovascular events among high-risk hypertensive patients.
NCT00139386	Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial	Completed	Japan Heart Foundation	Phase 4	2005-10-01	Candesartan is effective in preventing cardiovascular events in patients without restenosis after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after drug-eluting stent (DES) implantation was also effective in preventing cardiovascular events. The purpose of this study is to investigate whether an angiotensin II receptor blocker, candesartan, is effective in reducing the incidence of cardiovascular events after drug-eluting stent implantation.

Clinical Trial Conditions for Candesartan Cilexetil

Condition Name

Condition Name for Candesartan Cilexetil
Intervention	Trials
Hypertension	25
Essential Hypertension	5
Healthy	3
Congestive Heart Failure	2

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Candesartan Cilexetil
Intervention	Trials
Hypertension	26
Heart Failure	4
Diabetic Retinopathy	3
Stroke	3

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Candesartan Cilexetil

Trials by Country

Trials by Country for Candesartan Cilexetil
Location	Trials
United States	100
Japan	30
Korea, Republic of	20
United Kingdom	13
Canada	12

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Candesartan Cilexetil
Location	Trials
California	6
Florida	5
Texas	5
Ohio	5
North Carolina	5

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Candesartan Cilexetil

Clinical Trial Phase

Clinical Trial Phase for Candesartan Cilexetil
Clinical Trial Phase	Trials
Phase 4	10
Phase 3	23
Phase 2	5

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Candesartan Cilexetil
Clinical Trial Phase	Trials
Completed	37
Unknown status	9
Not yet recruiting	3

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Candesartan Cilexetil

Sponsor Name

Sponsor Name for Candesartan Cilexetil
Sponsor	Trials
AstraZeneca	19
Takeda	13
CJ HealthCare Corporation	7

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Candesartan Cilexetil
Sponsor	Trials
Industry	54
Other	13

Export unavailable in trial.
Subscribe for complete access.